Clinical trial of MK-2870 in people with previously treated endometrial cancer

This study is being conducted to test the safety of MK-2870. It will also investigate how well MK-2870 works compared to two standard chemotherapy regimens and whether participants receiving MK-2870 live longer and/or progression-free and have a better quality of life compared to those receiving standard chemotherapy. Around 710 patients are expected to participate worldwide. In Switzerland, around 20 patients are expected to take part in this study. MK-2870 is an experimental drug and belongs to the class of antibody-drug conjugates. It consists of an antibody that is linked to a chemotherapeutic agent. Antibodies bind to specific targets on cells and normally help the immune system to fight foreign substances such as bacteria or viruses. The antibody in MK2870 binds to the target TROP2 (trophoblast antigen 2), which is found on many cancer cells and only on a few normal cells. This brings the chemotherapeutic agent in MK2870 specifically into contact with cancer cells. In the current phase 1/2 trial (MK-2870-001), MK-2870 has shown promising activity as a monotherapy against tumors that were resistant to standard therapies. In this phase 3 trial, many more patients are now being tested to see whether these observations can be confirmed or not. Doxorubicin belongs to a group of drugs that can inhibit the growth of cells or kill them and is widely used in cancer therapy. It inhibits the production of nucleic acids, the components of a cell's genetic material. Paclitaxel also inhibits cell growth, but does so by interfering with cell division. The total duration of the study is approximately 4 years.

(BASEC)